NCT03206060 2026-04-01
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
Clinical Trials
21 trialsNCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
NCT06427798 2026-03-10
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT07150546 2026-03-02
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Phase 1 Recruiting
NCT04074135 2026-02-24
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06479811 2025-11-25
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT04609592 2025-09-09
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
Phase 1 Recruiting
NCT01879657 2025-08-06
68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)
Radio Isotope Therapy of America
Phase NA Completed
NCT06455358 2025-05-30
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
University Hospital, Basel, Switzerland
Phase 1/2 Recruiting
NCT01873248 2024-07-19
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT05069220 2024-03-01
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT03623984 2023-09-11
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
University of Alabama at Birmingham
Phase EARLY_PHASE1 Withdrawn
NCT00001277 2022-06-07
Studies of Elevated Parathyroid Activity
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01869725 2021-09-22
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
University of Iowa
Phase 2 Completed
NCT01619865 2021-07-27
GA-68
University of Iowa
Phase 1/2 Completed
NCT03001349 2021-02-15
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03197012 2020-07-07
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT01967537 2019-11-19
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02177773 2019-11-12
DOTA-TOC
University of California, San Francisco
Phase 1/2 Terminated
NCT04041882 2019-08-01
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT03057509 2019-06-21
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Massachusetts General Hospital
Phase 1 Withdrawn